# THE PHARMACOLOGICAL DEVELOPMENT OF IPW-5371 FUMARATE AS A RADIATION MEDICAL COUNTERMEASURE FOR THE TREATMENT OF DELAYED RADIATION LUNG INJURY UNDER THE FDA ANIMAL RULE

> **NIH NIH N01** · INNOVATION PATHWAYS, LLC · 2023 · $1,499,916

## Abstract

This proposal, using partial body irradiation (PBI) animal models to study the delayed effects of acute radiation exposure (DEARE) on survival due to multi-organ injury, including the lungs. The proposal is focused on supporting the critical path for FDA approval of an Innovation Pathways, small molecule TGFβ Receptor-1 kinase inhibitor MCM. Under the guidance criteria of the FDA “Animal Rule” (AR).

## Key facts

- **NIH application ID:** 10932585
- **Project number:** 75N93023C00014-0-9999-1
- **Recipient organization:** INNOVATION PATHWAYS, LLC
- **Principal Investigator:** BARRY HART
- **Activity code:** N01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2023
- **Award amount:** $1,499,916
- **Award type:** —
- **Project period:** 2023-07-01 → 2024-06-30

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10932585

## Citation

> US National Institutes of Health, RePORTER application 10932585, THE PHARMACOLOGICAL DEVELOPMENT OF IPW-5371 FUMARATE AS A RADIATION MEDICAL COUNTERMEASURE FOR THE TREATMENT OF DELAYED RADIATION LUNG INJURY UNDER THE FDA ANIMAL RULE (75N93023C00014-0-9999-1). Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/grant/nih/10932585. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*